SeekingAlpha · Aug 7, 2026
Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Stoke Therapeutics, Inc.
ST
NASDAQ · STOK
Stoke Therapeutics, Inc.
Healthcare · Biotechnology
$32.97
Down-$1.66 (-5.03%)
Updated Aug 13, 2026, 10:03 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.89B
- P/E ratio
- 47.82
- Dividend yield
- 0.00%
- 52-week range
- $27.24 – $40.22
- Volume
- 1.08M
- Avg. volume
- 1.2M
Price performance
STOK price history
1M range · 0 trading sessions · Daily adjusted prices
STOK does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest STOK news
The latest Smart Investors Daily articles mentioning STOK.
Stock researchCompany · Overview
STOK research
Overview
Company profile and research snapshot.
Company profile
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $30.33
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Guggenheim | Buy | — |
| Aug 4, 2026 | Wedbush | Outperform | — |
| Aug 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 4, 2026 | Chardan Capital | Buy | — |
| Jul 13, 2026 | Goldman Sachs | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 7, 2026
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?
Stoke Therapeutics (NasdaqGS:STOK) filed a shelf registration for a potential 2,000,000 common share offering reportedly tied to an Employee Stock Ownership Plan. The filing indicates possible future capital raising activity that could affect Stoke Therapeutics' capital structure and ownership mix. The ESOP related nature of the offering highlights employee equity participation as a factor in the company's compensation approach. To put this kind of equity move in context and see how other...
SeekingAlpha · Aug 5, 2026
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
Stoke Therapeutics stays a Buy as zorevunersen hits key Dravet milestones and STK-002 advances; strong cash runway to 2028. Click for more on STOK stock.
Yahoo · Aug 5, 2026
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
BEDFORD, Mass., August 05, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annu
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
